B. Swarovsky et al., TAMOXIFEN OR CYPROTERONE-ACETATE IN COMBINATION WITH BUSERELIN ARE INEFFECTIVE IN PATIENTS WITH PANCREATIC ADENOCARCINOMA, Oncology, 50(4), 1993, pp. 226-229
Experimental evidence and preliminary clinical data suggest a responsi
veness of pancreatic adenocarcinoma to sex hormones and LH-RH agonists
. In this study, we investigated the effect of the antiestrogen tamoxi
fen and the antiandrogen cyproterone acetate in combination with the L
H-RH agonist buserelin in 9 patients with unresectable pancreatic aden
ocarcinoma. In all patients the disease was progressive under this the
rapeutic regimen. In conclusion, complete androgen blockade and anties
trogens in combination with LH-RH agonist cannot be recommended in pat
ients with widespread pancreatic adenocarcinoma.